17-Apr-2026
Most shorted small cap stocks as of mid-April led by healthcare sector
Seeking Alpha News (Fri, 17-Apr 3:29 PM ET)
Recursion to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 7-Apr 8:00 AM ET)
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
Globe Newswire (Tue, 31-Mar 9:00 AM ET)
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
Globe Newswire (Wed, 25-Mar 7:59 AM ET)
Nvidia's Bet on Digital Biology and Stocks That Could Ride the Wave
Globe Newswire (Mon, 16-Mar 10:00 AM ET)
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Globe Newswire (Thu, 5-Mar 8:30 AM ET)
AI Biotech, APAC Expansion, and Balance Sheet Rebuilds Set the Morning Tone
Globe Newswire (Wed, 25-Feb 9:38 AM ET)
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Wed, 25-Feb 6:30 AM ET)
Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC
Globe Newswire (Mon, 23-Feb 8:00 AM ET)
Globe Newswire (Wed, 18-Feb 8:30 AM ET)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.
As of April 17, 2026, RXRX stock price climbed to $3.78 with 13,314,898 million shares trading.
RXRX has a beta of 3.00, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.34 to the broad based SPY ETF.
RXRX has a market cap of $1.97 billion. This is considered a Small Cap stock.
Last quarter Recursion Pharmaceuticals - Class A reported $36 million in Revenue and -$.21 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.09.
In the last 3 years, RXRX traded as high as $16.75 and as low as $2.80.
The top ETF exchange traded funds that RXRX belongs to (by Net Assets): ARKK, XBI, VTI, ARKG, IWM.
RXRX has underperformed the market in the last year with a return of -31.3%, while the SPY ETF gained +36.3%. In the last 3 month period, RXRX fell short of the market, returning -19.1%, while SPY returned +2.9%. However, in the most recent 2 weeks RXRX has outperformed the stock market by returning +21.5%, while SPY returned +8.3%.
RXRX support price is $3.45 and resistance is $3.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.